Table 1 Baseline characteristics of patients in the study.
From: Prognostic and predictive value of a lncRNA signature in patients with stage II colon cancer
Training | Cohort | n = 141 | p | Test | Cohort | n = 63 | p | P* | |
|---|---|---|---|---|---|---|---|---|---|
Total | Low risk | High risk | Total | Low risk | High risk | ||||
Gender | |||||||||
Female | 64 | 50 (45.9%) | 14 (43.8%) | 0.992 | 28 | 22 (43.1%) | 6 (50%) | 0.914 | 0.998 |
Male | 77 | 59 (54.1%) | 18 (56.2%) | 35 | 29 (56.9%) | 6 (50%) | |||
Lymphatic invasion | |||||||||
No | 104 | 84 (81.6%) | 20 (76.9%) | 0.798 | 49 | 40 (81.6%) | 9 (75%) | 0.910 | 0.997 |
Yes | 25 | 19 (18.4%) | 6 (23.1%) | 12 | 9 (18.4%) | 3 (25%) | |||
Microsatellite instability | |||||||||
No | 23 | 22 (81.5%) | 1 (50%) | 0.876 | 10 | 9 (81.8%) | 1 (50%) | 0.944 | 0.912 |
Yes | 6 | 5 (18.5%) | 1 (50%) | 3 | 2 (18.2%) | 1 (50%) | |||
T stage | |||||||||
T3 | 132 | 104 (95.4%) | 28 (87.5%) | 0.231 | 59 | 49 (96.1%) | 10 (83.3%) | 0.331 | 0.996 |
T4 | 9 | 5 (4.6%) | 4 (12.5%) | 4 | 2 (3.9%) | 2 (16.7%) | |||
Venous invasion | |||||||||
No | 106 | 86 (87.8%) | 20 (87%) | 0.998 | 49 | 39 (83%) | 10 (83.3%) | 0.926 | 0.551 |
Yes | 15 | 12 (12.2%) | 3 (13%) | 10 | 8 (17%) | 2 (16.7%) | |||
Agea | |||||||||
Younger | 75 | 57 (52.3%) | 18 (56.2%) | 0.847 | 31 | 25 (49%) | 6 (50%) | 0.981 | 0.710 |
Older | 66 | 52 (47.7%) | 14 (43.8%) | 32 | 26 (51%) | 6 (50%) | |||
LN count | |||||||||
Fewer_than_12 | 16 | 14 (13.6%) | 2 (7.7%) | 0.629 | 8 | 7 (14.3%) | 1 (8.3%) | 0.944 | 0.998 |
12_or_more | 113 | 89 (86.4%) | 24 (92.3%) | 53 | 42 (85.7%) | 11 (91.7%) | |||
CEA | |||||||||
Normal | 60 | 46 (75.4%) | 14 (73.7%) | 0.996 | 29 | 24 (82.8%) | 5 (71.4%) | 0.883 | 0.681 |
Abnormal | 20 | 15 (24.6%) | 5 (26.3%) | 7 | 5 (17.2%) | 2 (28.6%) | |||
